Boards

Science Advisory Board

Edward W. Martin, JR, MD, FACS – Company Founder/ Chief Medical Officer/

Science Board Chair

 

 

 

 

 

 

Click for Bio

 Dr. Martin is a Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. Dr. Martin’s vision of intraoperative assessment of tumor biology and dissemination has spanned nearly 30 years of progress at OSU. Leading a team of innovators beginning in 1979, Dr. Martin developed the first hand-held probe capable of detecting cancer cells of colorectal, pancreatic, gastric, ovarian, prostatic, and breast origin in real-time in the operating room. The use of such hand-held probes has become the standard of care in the surgical management of many malignant and benign disease processes. Dr. Martin has significant patent and commercialization experience. His endeavors have generated six patents, and spawned four start-up companies which have developed an additional 78 U.S. patents.

Dr. Martin holds a degree in Medicine from Meharry Medical College (Nashville, TN) and completed his surgical training at OSU (Columbus, OH). His specialty training includes National Institutes of Health (NIH), OSU, and American Cancer Society Advanced Fellowship.

Thomas Magliery, PhD – Chief Science Officer

Click for Bio

 Dr. Magliery has substantial expertise in protein design, directed evolution and biophysical characterization, as well as enzymological characterization. As an independent investigator, Dr. Magliery has invented a  high-throughput screen for protein thermal stability, used bioinformatics to design stable proteins, and continued to improve chemical biology methods for studying weak protein interactions in cells. Dr. Magliery has studied the enzymology and engineered the physical properties of paraoxonase-1 for chemical warfare countermeasures. In 2012, Dr. Magliery began an effort to engineer stable, high-affinity antibody fragments for use in cancer imaging which has demonstrated that several of these are effective in xenograft mice.
  As a postdoctoral fellow with Lynne Regan, Dr. Magliery developed a cell-based screen for application of combinatorial methods to protein design, applied statistical analysis to the design of protein motifs, and made substantial improvements to a GFP-based method for trapping protein interactions in living cells. As a graduate student with Peter Schultz, Dr. Magliery engineered orthogonal enzyme-tRNA pairs by directed evolution, and engineered expanded-codon tRNAs, leading to the first living organisms capable of site-specific insertion of unnatural amino acids. In 8 years at OSU, Dr. Magliery has graduated 7 Ph.D. students, 2 M.S. students, and 10 senior honors students. His lab currently hosts 9 graduate students and 3 postdocs, as well as 6 undergraduate researchers and 2 research assistants/technicians.

George H. Hinkle, MS, RPh – Chief Informations Officer

 

 

 

 

 

 

Click for Bio

 Mr. Hinkle is an Associate Professor of Pharmacy and Radiology at The Ohio State University (OSU). He has more than 25 years experience in radiopharmaceutical research/development primarily with radiolabeled antibodies and small molecules for tumor targeting. Mr. Hinkle has experience in leading clinical trials involving radiopharmaceuticals and will coordinate the laboratory development, pre-clinical chemistry and animal imaging of radiolabeled compounds using MicroPET/CT and tissue distribution/pharmacokinetic studies.

Mr. Hinkle holds a degree in Pharmacy and a masters degree in Nuclear Pharmacy, both from Purdue University (West Lafayette, IN)

Mr. Hinkle provides expertise in the clinical use of radiopharmaceutical agents, as Enlyton moves radiolabeled compounds into the clinical testing stages.

David Colcher, PhD

dave

 

 

 

 

 

 

Click for Bio

 Dr. Colcher has over 30 years of experience using MAbs for preclinical and clinical use, bothin vitro and in vivo in model systems and in numerous clinical studies. Dr. Colcher began these studies by developing antibodies tumor associated antigens while at the National Cancer Institute. In collaboration with Jeffrey Schlom, Dr. Colcher developed a number of antibodies to tumor associated antigens that are well recognized in the field, especially anti-TAG-72 MAbs. This translational work involving animal imaging studies resulted in the submission of a number of INDs resulting clinical trials for the localization and treatment of solid tumors. These initial studies were with solid tumor antigens that have since been licensed and are under development by several different companies. After 18 years at the NCI Dr. Colcher moved to the University of Nebraska Medical Center as a Professor in the Departments of Pathology and Microbiology, Radiology and at the Eppley Institute as well as being a Member of the NCI designated Cancer Center. Dr. Colcher was the Director of the Radiopharmacy and was directly involved in developing the use of radiolabeled antibodies for imaging and therapy at UNMC both for preclinical and clinical studies. In 1999 Dr. Colcher moved to a biotechnology company where he was involved in the development, manufacturing and Quality Control of a radiolabeled antibody for the treatment of lymphoma. Since joining the City of Hope in 2002 Dr. Colcher assumed responsibility for the radioimmunotherapy and immunotherapy studies in the Department of Cancer Immunotherapeutics & Tumor Immunology as well as becoming the Director of the Investigational Radiopharmacy and Director of the Small Animal Imaging Core. Dr. Colcher is involved in both preclinical and clinical radioimmunotherapy and immunotherapy studies in lymphoma and solid tumors.

Louis R. DePalatis, PhD

Untitled

 

 

 

 

 

 

 

Click for Bio

 Dr. DePalatis serves as Director of Technology and Business Development in the Center for Advanced Biomedical Imaging (CABI) at the University of Texas MD Anderson Cancer Center in Houston, Texas.  He has held this position for over 9 years during which, he was responsible for working with faculty and staff within The Division of Diagnostic Imaging to advance a number of research projects related to technology development for targeting and imaging various types of cancer.  In addition, Dr. DePalatis was responsible for grant mentoring of young investigators, development of an Intellectual Property portfolio, facilitation of the organization and development of the CABI and other activities, as needed.  Prior to his current appointment, Dr. DePalatis worked in pharmaceutical, biotechnology and diagnostic imaging companies for 24 years.  During this period of time, he played key roles in research and development of small molecules and monoclonal antibodies as radiopharmaceutical agents for diagnosis and treatment of cancer.  Dr. DePalatis is also active on a number of committees within MD Anderson and in several professional and scientific organizations.

Dr. DePalatis obtained his Bachelor of Science degree from Slippery Rock University, a Master of Science degree from Southern Illinois University and a Ph.D. degree in Physiology from The Ohio State University.

Richard Hoefer, DO, FACS

hoeffer

 

 

 

 

 

 

 

 

 

Click for Bio

 Dr. Hoefer is a practicing Surgical Oncologist in Hampton Roads, Virginia. Dr. Hoefer completed his Surgical Oncology Fellowship at the University of Texas, M.D. Anderson Cancer Center.   Dr. Hoefer is an Assistant Professor of Clinical Surgery at Eastern Virginia Medical School, Co-Director of the Sentara Dorothy G. Hoefer Comprehensive Breast Center, and Medical Director of the Sentara Cancer Network.  Under his leadership, the center has been a highly innovative, multidisciplinary model offering tomosynthesis, Breast Specific Gamma Breast Imaging, Radioiodine Seed Localizing procedures, Intraoperative Radiation for early stage breast cancer and a variety of clinical research trials (e.g., Alliance, NSABP,  RTOG,  and US Oncology protocols).   He developed the Sentara Pancreatic Consortium in collaboration with Sentara Cancer Network pancreatic surgeons.
His interests include Breast, Pancreatic, Ovarian, Gastric, and Colorectal Cancer and Melanoma.
Dr. Hoefer has a special interest in molecular imaging, and helped develop the prototype for the Breast Specific Gamma Imaging Device designed by the Jefferson Labs in Newport News and at Hampton University.  He has developed prototypes within the lab and shares a patent with their researchers for molecular imaging of resected breast tumors.   Dr. Hoefer holds a medical degree from the Philadelphia College of Osteopathic Medicine, and performed a General Surgery Residency at Wilford Hall USAF Medical Center.

Lester S. Johnson, MD, PhD, FACR

Lester

 

 

 

 

 

 

 

Click for Bio

 Dr. Johnson is a practicing radiologist in Medical Center Radiologists (MCR) of Virginia Beach, VA, and serves as Medical Director of Nuclear Medicine and PET/CT (including three PET/CT programs and nuclear medicine at three hospitals and two imaging centers). At Eastern Virginia Medical School (EVMS), Norfolk, VA, Dr. Johnson is Chairman of the Department of Radiology for ten years and also Radiology Residency Program Director. Dr. Johnson completed the MD/PhD Program at Columbia University College of Physicians and Surgeons in NY, NY in 1995, under the NIH Medical Scientist Training Program. His PhD thesis was in molecular cell biology, focused on studying membrane receptor trafficking. He then completed his residency in radiology at the Columbia-Presbyterian Medical Center in NY, followed by his fellowship in nuclear medicine at the Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO in 2000. Dr. Johnson is double board certified in nuclear medicine and in radiology, with special competence/CAQ in nuclear radiology. Dr. Johnson serves as the radiology representative on the Sentara Cancer Network Committee.   He serves as the Chairman of the Radiation Safety Committee for Sentara Southside Hospitals. Besides his academic roles at EVMS noted above, Dr. Johnson is Adjunct Clinical Professor at Old Dominion University where he serves as Medical Director of the Nuclear Technologist Training Program. Lester serves for the American Board of Radiology, where he was an examiner in nuclear radiology for numerous years. Dr. Johnson has been recognized multiple times as a “Top Doc” in Hampton Roads/Coastal Virginia by the Hampton Roads Magazine (now the Coastal Virginia Magazine). This year Dr. Johnson was inducted into Fellowship by the American College of Radiology, an honor the ACR bestows to only 10% of radiologists.

Michael F. Tweedle, PhD

tweedle

 

 

 

 

 

 

 

 

Click for Bio

 Dr Tweedle has extensive experience in the characterization and biologic validation of parenteral imaging pharmaceuticals, including clinical translation. Dr Tweedle has invented new imaging agents, directed drug discovery programs, and led translational development of pharmaceuticals including one the first commercial MRI agents (ProHanceTM).   His research groups have created X ray, MRI, radiopharmaceutical and targeted US agents for clinical evaluation, through the CMC and IND filing stages. Dr Tweedle’s Molecular Imaging Agents Laboratory at OSU synthesizes and characterizes new and complex small molecules, peptides and proteins, cultures and transfects human and veterinary cancer cells, creates xenograft and orthotopic mice models, radiolabeled tracers, and performs spectroscopic, in vitro, ex vivo and in vivo biodistributions, pharmacokinetics, target binding, stability and micro-imaging studies. His current research interests are in creation and development of molecular imaging and theranostic pharmaceuticals for MRI, PET/SPECT and optical imaging of cancer.

 

 

Board of Directors

Herbert Neuman, MD, MBA – Chief Executive Officer/Board Member

Herbert Neuman, MD, MBA 300dpi

 

 

 

 

 

 

Click for Bio

Dr. Neuman serves as Enlyton’s Chief Executive Officer and member of the Board of Directors. Dr. Neuman brings his strong background as a senior bio-pharmaceutical executive to our team. His experience in drug development and regulatory affairs will help drive the success of our ENL 210 clinical development program and subsequent approval by the FDA and other health authorities.

Board-certified in Internal Medicine, Dr. Neuman left clinical practice to join the pharmaceutical industry. During the course of his pharmaceutical career, he held a variety of senior executive positions, including Vice President of Global Regulatory Affairs, Vice President of Medical Affairs and Chief Medical Officer of a Fortune 500 global healthcare company. Throughout these roles, he successfully led efforts to gain initial marketing approval or expanded indications for multiple products around the world, including a wide-range of imaging diagnostics.
Dr. Neuman provides Enlyton with strategic guidance in the areas of new product regulatory pathways, product lifecycle management, business development & investment strategies, executive talent development, medical affairs, and drug safety. He is well-regarded as a leader in the area of advocacy before the US FDA, having extensive experience in articulating the risks and benefits of medicinal and diagnostic products to the FDA, including multiple face-to-face meetings at the FDA as well as at FDA public hearings and Advisory Committee meetings.

Edward W. Martin, Jr, MD, FACS – Founder — Board Chair

 

 

 

 

 

 

Click for Bio

 Dr. Martin is a Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. Dr. Martin’s vision of intraoperative assessment of tumor biology and dissemination has spanned nearly 30 years of progress at OSU. Leading a team of innovators beginning in 1979, Dr. Martin developed the first hand-held probe capable of detecting cancer cells of colorectal, pancreatic, gastric, ovarian, prostatic, and breast origin in real-time in the operating room. The use of such hand-held probes has become the standard of care in the surgical management of many malignant and benign disease processes. Dr. Martin has significant patent and commercialization experience. His endeavors have generated six patents, and spawned four start-up companies which have developed an additional 78 U.S. patents.

Dr. Martin holds a degree in Medicine from Meharry Medical College (Nashville, TN) and completed his surgical training at OSU (Columbus, OH). His specialty training includes National Institutes of Health (NIH), OSU, and American Cancer Society Advanced Fellowship.

Rodney Prosser, Owner/Managing Partner Nuclear Diagnostics Products

Feb 2016 take 2 015-2

Click for Bio

Mr. Prosser is currently a partner and employee of Nuclear Diagnostic Products Inc. Nuclear Diagnostic Products operates three centralized nuclear pharmacies in the New York / Philadelphia area providing time critical unit dose prescriptions to the medical community.

Mr. Prosser started his career as a Nuclear Pharmacist in 1977 as an employee of the Joint Program of Nuclear Medicine. The Joint Program of Nuclear Medicine is a co-op that included Harvard Medical School and eight hospitals in the Boston area. From there, he moved on to other employment opportunities that included the operation of centralized nuclear pharmacies. As a result of mergers and corporate realignments, he held positions as a Staff Pharmacist, Pharmacy Manager, Regional Manager and General Manager with Nuclear Pharmacy Incorporated / Pharmatopes (Syncor International). In addition to Nuclear Pharmacy, he was employed as a hospital pharmacist for a two year period from 1980 to 1982.

During the past ten years he has served as a Member of the Board with several small companies including United Pharmacy Partners Inc.

 

Jeff Walker, MBA, Senior Executive Business Director, James Cancer Hospital and Solove Research Institute

Walker Jeff1381

Click for Bio

 For the past six years Jeff A. Walker has been the first executive director for The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

In this role, Walker oversees all administrative, operational and fiscal functions for Ohio State’s cancer program, which includes the James Cancer Hospital and Solove Research Institute, the first and only free-standing cancer hospital in Ohio, and The Ohio State University Comprehensive Cancer Center, with more than 270 researchers from 13 colleges at Ohio State.

With more than 10 years of previous administrative leadership experience at the University of Pittsburgh Cancer Institute, Walker was recruited and served from 2001 to 2007 as associate director of Ohio State’s Comprehensive Cancer Center.

Most recently, Walker has served as executive vice president for Roswell Park Cancer Research Institute in Buffalo, NY, where he has overseen the development, direction and operation of the Institute including the administrative, scientific and clinical departments, all mission area programs, strategic planning initiatives and the renewal of the National Cancer Institute core grant.

Walker earned his bachelor’s degree in biochemistry from Pennsylvania State University and a master’s degree in business administration from the University of Pittsburgh. He has served on the finance and investment committee of the Association of American Cancer Institutes, and is a member of the Alliance of Dedicated Cancer Centers, Cancer Center Administrators Forum and the Medical Group Management Association